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Introduction: Breast cancer progression is promoted by stromal cells that populate the tumors, including
cancer-associated fibroblasts (CAFs) and mesenchymal stem/stromal cells (MSCs). The activities of CAFs and
MSCs in breast cancer are integrated within an intimate inflammatory tumor microenvironment (TME) that includes
high levels of tumor necrosis factor α (TNF-α) and interleukin 1β (IL-1β). Here, we identified the impact of TNF-α
and IL-1β on the inflammatory phenotype of CAFs and MSCs by determining the expression of inflammatory chemokines
that are well-characterized as pro-tumorigenic in breast cancer: CCL2 (MCP-1), CXCL8 (IL-8) and CCL5 (RANTES).
Methods: Chemokine expression was determined in breast cancer patient-derived CAFs by ELISA and in patient
biopsies by immunohistochemistry. Chemokine levels were determined by ELISA in (1) human bone marrow-derived
MSCs stimulated by tumor conditioned media (Tumor CM) of breast tumor cells (MDA-MB-231 and MCF-7) at the end
of MSC-to-CAF-conversion process; (2) Tumor CM-derived CAFs, patient CAFs and MSCs stimulated by TNF-α (and IL-1β).
The roles of AP-1 and NF-κB in chemokine secretion were analyzed by Western blotting and by siRNAs to c-Jun and
p65, respectively. Migration of monocytic cells was determined in modified Boyden chambers.
Results: TNF-α (and IL-1β) induced the release of CCL2, CXCL8 and CCL5 by MSCs and CAFs generated by prolonged
stimulation of MSCs with Tumor CM of MDA-MB-231 and MCF-7 cells. Patient-derived CAFs expressed CCL2 and CXCL8,
and secreted CCL5 following TNF-α (and IL-1β) stimulation. CCL2 was expressed in CAFs residing in proximity to breast
tumor cells in biopsies of patients diagnosed with invasive ductal carcinoma. CCL2 release by TNF-α-stimulated MSCs was
mediated by TNF-RI and TNF-RII, through the NF-κB but not via the AP-1 pathway. Exposure of MSCs to TNF-α led to potent
CCL2-induced migration of monocytic cells, a process that may yield pro-cancerous myeloid infiltrates in breast tumors.
Conclusions: Our novel results emphasize the important roles of inflammation-stroma interactions in breast cancer, and
suggest that NF-κB may be a potential target for inhibition in tumor-adjacent stromal cells, enabling improved tumor con-
trol in inflammation-driven malignancies.Introduction
The development and progression of breast tumors are
multifactorial processes that are influenced by the tumor
microenvironment (TME). Recent studies demonstrated
that breast tumors are populated by myofibroblasts that
express pro-cancerous functions [1-4], known as cancer-* Correspondence: aditbb@tauex.tau.ac.il
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cells may exist, including resident tissue fibroblasts and
mesenchymal stem/stromal cells (MSCs) that have been
continuously exposed to tumor-derived and TME con-
stituents. Such MSCs, originating in bone marrow (BM)
or adipose tissues generally have pro-cancerous effects
that promote malignancy in many tumor systems, in-
cluding breast cancer [5-12]. In vitro, tumor cell prod-
ucts that are present in tumor-derived conditioned
medium (CM) convert MSCs to CAFs which becomearticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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in vivo [11-14].
The activities of CAFs and MSCs do not take place in
the void, but rather are integrated in their intimate
TME. In many cancers, the TME is dominated by in-
flammatory elements, including inflammatory leukocytes
and inflammatory soluble factors that generally promote
disease progression [15-18]. The inflammatory cytokines
tumor necrosis factor alpha (TNF-α) and interleukin
1β (IL-1β) are often present in the inflammatory milieu of
many tumors. In contrast to tumor-cytotoxic effects
caused by acute local TNF-α administration, chronic and
persistent presence of TNF-α in tumors has strong pro-
tumoral effects in many cancers [19-21]. Accordingly,
inhibition of TNF-α or its receptors has prominent anti-
tumor effects in animal models of breast cancer [22-29].
In parallel, major causative pro-tumoral roles were at-
tributed to IL-1β in breast cancer via angiogenesis and
matrix-remodeling activities [30-37]. Overall, based on
recent studies addressing the roles of TNF-α and IL-1β in
malignancy, both cytokines are now considered potential
targets for therapy in cancer [32,38-40].
We recently reported that TNF-α and IL-1β were min-
imally expressed by normal breast epithelial cells, but
were highly expressed in tumor cells of biopsies from
most breast cancer patients [41]. In such individuals, the
elevated expression of TNF-α and IL-1β was significantly
correlated with relapse and advanced disease [41-49].
Despite emerging information on the impact of these in-
flammatory cytokines on tumor-promoting events in
stromal cells [10,50-55], their ability to shape the inflam-
matory phenotype of CAFs and MSCs has been only
partly revealed.
Recent studies indicate that CAFs and MSCs promote
malignancy through the expression of inflammatory che-
mokines [4,54-65]. In this respect, inflammatory chemo-
kines such as CCL2 (monocyte chemoattractant protein
1 MCP-1), CXCL8 (IL-8) and CCL5 (RANTES) are of
major relevance because they promote aggressiveness in
tumor cells, they induce tumor-supporting effects in
cells of the TME, and they play direct roles in advancing
tumor growth and metastasis in many cancer diseases,
including cancer of the breast [21,66-70]. MSC-derived
and CAF-derived inflammatory chemokines promote
tumor progression by inducing the infiltration of pro-
tumorigenic myeloid cells to tumors (such as tumor-
associated macrophages (TAMs) and myeloid-derived sup-
pressor cells (MDSCs) [17,67,71-75]), increasing angiogen-
esis, elevating tumor cell stemness, invasion and proliferation,
and promoting the recruitment of MSCs to primary tu-
mors and metastases [4,54-65]. Overall, the outcome
of such chemokine activities is a pronounced promo-
tion of cancer progression and tumor cell dissemin-
ation to distant organs.Our overall goal in this study was to investigate as-
pects of inflammation–stroma interactions in breast can-
cer. To this end, we determined the influence of breast
tumor-derived factors and of inflammatory cytokines on
the inflammatory phenotype of CAFs and MSCs, mani-
fested by the release of the pro-cancerous chemokines
CCL2, CXCL8 and CCL5 by these cells. The novel find-
ings obtained in this study show intensive inflamma-
tion–stroma interactions that act specifically through the
designated pathway of nuclear factor κB (NF-κB) activation
in stromal cells. Through these interactions, the inflam-
matory microenvironment shapes the tumor-promoting
phenotype of MSCs and CAFs and may thus enhance
tumor progression.
Methods
Breast tumor cell cultures
Human breast tumor MDA-MB-231 cells were obtained
from ATCC (Manassas, VA, USA) and MCF-7 cells were
kindly provided by Prof. Kaye, Weizmann Institute of
Science, Rehovot, Israel. The MCF-7 cells were authenti-
cated on the basis of published characteristics of MCF-7
cells [76,77] by verifying that they express an active es-
trogen receptor alpha, respond to estrogen, express low
levels of ErbB2, form tumors upon supplementation of
estrogen and matrigel, and have low metastatic potential.
These cells were grown in enriched Dulbecco’s modified
Eagle’s medium (DMEM), including 10% fetal bovine
serum (FBS), 100 U/ml penicillin, 100 μg/ml strepto-
mycin, 250 ng/ml amphotericin, and 4 mM L-glutamine
(Biological Industries, Beit Ha’emek, Israel).
Isolation of CAFs from patient breast tumors
CAFs were obtained from surgically resected breast tu-
mors of patients who provided written informed consent
as approved by the Institutional Review Board of Sheba
Medical Center. Tissues were cut into small pieces,
shaken overnight at 37°C in collagenase type 4 (250 U/
ml, #S3J6523; Worthington Biochemical, Lakewood, NJ,
USA) in DMEM, filtered (100 mm cell strainer; BD Biosci-
ences, San Jose, CA, USA) and plated in DMEM supple-
mented with 20% FBS, 1 mM sodium pyruvate, 2 mM
L-glutamine, minimum essential medium nonessential
amino acids, antibiotics and 60 mM β-mercaptoethanol
(Biological Industries; and Sigma-Aldrich, St. Louis,
MO, USA). Cells propagated in these conditions had
typical fibroblastic phenotype: their identity was verified
by the absence of the epithelial marker cytokeratin and
the presence of the typical mesenchymal markers vimen-
tin, α-smooth muscle actin (αSMA), fibroblast-specific
protein 1 (FSP1) and fibroblast-activation protein alpha
(FAPα) (Figure S1 in Additional file 1). The cells were rou-
tinely grown in medium as above or in Eagle’s minimum
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regular tissue culture additives.
Two human patient-derived CAF isolates were gen-
erated and characterized for CAF phenotype as
described above. CAFs #1 cells were derived from a
lung metastasis of breast cancer and were immor-
talized by human telomerase reverse transcriptase
(hTERT), as described previously [78]. CAFs #2 cells
were derived from a primary breast tumor of a differ-
ent patient and were kept in culture without hTERT
immortalization.
Origins and growth of MSCs
Two sources of human BM-derived MSCs of healthy in-
dividuals were used in the study. First, in the earlier
stages of the study, human MSCs were isolated from un-
processed BM of healthy individuals obtained from
Lonza (Walkersville, MD, USA; Cambrex at that time)
and were cultured in mesencult medium (#05411; Stem-
cell Technologies Inc., Vancouver, BC, Canada). Follow-
ing establishment in culture, the isolated MSCs were
cultured in α-minimum essential medium containing
10% FBS and penicillin-streptomycin (as in [13]). In line
with typical characteristics of MSCs, the isolated cells
expressed CD44, CD105, CD90, HLA-ABC and Stro1,
while they were negative for CD45, HLA-DR and CD11b
(see [13]; data not shown), as determined by flow cytom-
etry using FITC-labeled antibodies (BD Biosciences).
Expanded cultures of human BM-derived MSCs were
analyzed for adipogenic, osteogenic and myogenic differ-
entiation in vitro, to determine multipotency (data not
shown). Second, at the advanced stages of the study,
fully characterized MSCs were purchased from Lonza.
As indicated in Lonza’s datasheet, the cells had typical
MSC characteristics. They expressed CD44, CD29,
CD105, and CD166 and did not express CD45, CD14
and CD34. Also, the cells can differentiate to adipogenic,
chondrogenic and osteogenic lineages when cultured in
the recommended differentiation medium. The cells
were thawed into enriched mesencult medium (Stemcell
Technologies Inc.) and then were subcultured every 5 to
7 days in enriched DMEM medium. In all cases, cell
growth was continued in DMEM medium for a limited
number of passages (generally up to 10 passages).
Long-term growth of MSCs with Tumor CM, followed by
TNF-α stimulation
MDA-MB-231 and MCF-7 breast tumor cells were
grown in enriched DMEM culture medium (as above).
Tumor CM from these cancer cells was collected after
18 to 24 hours, centrifuged at 1,200 rpm for 5 minutes
and supernatants were passed through sterile filters with
0.45 μm polyvinylidene difluoride membrane (Millipore,
Bedford, MA, USA). MSCs were exposed to such freshTumor CM twice a week for a ~30-day time period, fol-
lowing the protocol described in [13] that has generated
CAFs which promoted tumor growth in vivo in past ex-
periments [13]. In parallel, control MSCs from the same
initiating cell stock were cultured with enriched DMEM
medium. To verify the CAF-like phenotype of cells gen-
erated by this process (termed herein CAFs), in this
study we used criteria of modified morphology and typ-
ical CAF markers: the expression of vimentin, upregula-
tion of αSMA expression (Figure S2 in Additional file 1)
and elevated expression of FSP1 (performed for MCF-7
CM only; data not shown).
CAFs obtained by stimulating MSCs for ~30 days and
their control MSCs were trypsinized, centrifuged and
counted. The cells were plated at equivalent density
and, following an additional 24 hours of incubation,
supernatants from the differentiated CAFs and from
control MSCs were frozen in −20°C. In parallel, an ali-
quot of the original Tumor CM was frozen at −20°C.
All supernatants were then thawed at the same time
(from CAFs obtained by incubation with Tumor CM,
from control MSCs that were grown for the same time
period and the CM of the tumor cells themselves) for
determination of CCL2, CXCL8 and CCL5 levels in
these supernatants by enzyme-linked immunosorbent
assay (ELISA).
In other assays, this same procedure was utilized in
the presence of short stimulation by TNF-α (50 ng/ml;
PeproTech, Rocky Hill, NJ, USA), carried out during
the last 24 hours of culture. TNF-α working concentra-
tions were chosen based on criteria described next in
Stimulation of MSCs by TNF-α or IL-1β. As control for
TNF-α, the cells were incubated with the vehicle of the
cytokine (0.1% bovine serum albumin (BSA)). CCL2,
CXCL8 and CCL5 levels in cell supernatants were deter-
mined by ELISA.
Stimulation of MSCs by TNF-α or IL-1β
MSCs were cultured for 24 hours in enriched DMEM
medium. The medium was then removed, and cells were
incubated for 24 hours in medium containing TNF-α (50
ng/ml) or IL-1β (500 pg/ml) (PeproTech). Cytokine
working concentrations were chosen based on calibra-
tions performed in other cell systems in our laboratory
and are in the accepted range used in vitro in other
studies (several selected publications [79-81]). Chemo-
kine expression in cell supernatants was determined by
ELISA. In controls, we verified that the vehicle of the cy-
tokines (0.1% BSA) did not induce chemokine release by
the MSCs.
In specific cases, neutralizing antibodies or small interfering
RNAs (siRNAs) were used. For experiments with antibodies
to TNF-α receptors, MSCs were plated in enriched DMEM
medium for 24 hours. The cells were then washed and
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FBS, in the presence of neutralizing antibodies for tumor
necrosis factor receptors TNF-RI and TNF-RII (10 μg/ml,
#MAB225 and #MAB726, respectively; R&D Systems,
Minneapolis, MN, USA) or isotype-matched nonrelevant
antibody control (10 μg/ml, #400101; BioLegend, Roselle,
San Diego, USA) for 1 hour. Antibody concentrations
were chosen based on preliminary analyses, in which sev-
eral concentrations of neutralizing antibodies were tested
(data not shown). Following this incubation period, TNF-α
(50 ng/ml) or its vehicle (as above) was added to cells.
After 24 hours, cell supernatants were collected for ELISA
assays.
For experiments with siRNAs to c-Jun or p65,
MSCs were plated in enriched DMEM medium for 24
hours. The cells were then transiently transfected with
siRNA to c-Jun (60 nM, #L-003268-00; Dharmacon,
Lafayette, CO, USA), siRNA to p65 (30 nM, #MU-
003533-02; Dharmacon; kindly provided by Prof. Wie-
mann, DKFZ, Heidelberg Germany) or control siRNA
(same concentrations) by Lipofectamine RNAiMAX™
transfection reagent (Life Technologies, Grand Island,
NY, USA) according to the manufacturer’s instruc-
tions. The cells were washed and incubated in DMEM
medium overnight, and then stimulated with TNF-α
(25 ng/ml; a suboptimal concentration of TNF-α was
used in order to facilitate detection of inhibitory
effects) for 24 to 48 hours. Cell supernatants were
collected for ELISA assays.MSC stimulation by CM derived from MDA-MB-231 cells,
transfected with TNF-α-expressing vector
MDA-MB-231 cells were transiently transfected with
pcDNA3.1 vector or with the same vector coding for
human TNF-α, by ICAFectin™ 441 DNA transfection re-
agent (InCellArt, Nantes, France) according to the man-
ufacturer’s instructions. After 24 hours, Tumor CM was
harvested and TNF-α expression was determined by
ELISA, as described below. In parallel, on the day of
MDA-MB-231 cell transfection, MSCs were plated in
enriched DMEM medium. The MSCs were then incu-
bated for 24 hours with Tumor CM from MDA-MB-231
cells transfected by control vector or by TNF-α-expressing
vector, or with enriched DMEM medium as control.
Part of the above MDA-MB-231 Tumor CM was frozen
in −20°C, as was also the case for CM of MSCs alone.
All CM was then thawed at the same time (from MSCs
stimulated with supernatants of MDA-MB-231 cells
transfected by control vector or by TNF-α-expressing
vector, from control MSCs and the CM of the tumor
cells themselves). As appropriate, CCL2, CXCL8, CCL5
and TNF-α levels in these supernatants were deter-
mined by ELISA.Stimulation of patient CAFs by TNF-α and IL-1β
CAFs #1 and CAFs #2 isolates were cultured for 24
hours in CAF growth medium (as above). The cells were
then washed twice in LPM starvation medium (Bio-
logical Industries), and incubated for 48 hours in LPM
starvation medium in the presence of TNF-α (50 ng/ml),
IL-1β (500 pg/ml) or cytokine vehicle (as above). CCL5
levels in the supernatants of the cells were determined
by ELISA.Confocal analyses
Human BM-derived MSCs that were grown in the ab-
sence of or in the presence of MDA-MB-231-derived or
MCF-7-derived Tumor CM for ~30 days (as above) were
cultured for 24 hours on sterilized cover slips at 37°C.
The cells were washed, fixed in 8% paraformaldehyde,
permeabilized with 0.2% triton, blocked with 2% BSA in
PBS, and then incubated with antibodies against αSMA
(#A-2547; Sigma-Aldrich) and vimentin (#sc-6260; Santa
Cruz Biotechnology, Santa Cruz, CA, USA). Negative
controls included samples in which the primary anti-
bodies were replaced by isotype-matched nonrelevant
antibody controls (data not shown). The cells were then
stained with the secondary antibodies, as appropriate. In
parallel, cells were counterstained with the nuclear dye
4′,6-diamidino-2-phenylindole. Cell-coated cover slips
were removed from the wells, embedded in mounting
gel and imaged by confocal microscopy (Zeiss LSM 510;
Carl Zeiss AG, Oberkochen, Germany).Polymerase chain reactions (PCR)
To determine the expression of human TNF receptors,
total RNA was isolated by the EZ-RNA kit (#20-400-
100; Biological Industries) from patient CAFs #1 and
CAFs #2 isolates, from MSCs and from HL-60 cells that
served as positive control. First-strand complementary
DNA was generated using the M-MLV reverse transcript-
ase (#AM2044; Ambion, Austin, TX, USA). The expres-
sion of TNF-RI (TNFRSF1A) and TNF-RII (TNFRSF1B)
was determined using the following primers: TNF-RI,
forward 5′-GCACTGCCGCTGCCACACT-3′ and re-
verse 5′-AAGGCGATCTCGCAGGACG-3′, expected
PCR product size 1,480 base pairs; and TNF-RII, for-
ward 5′-ATGGCGCCCGTCGCCGTCT-3′ and reverse
5′-CCTGGTTAACTGGGCTTCATC-3′, expected PCR
product size 1,390 base pairs. PCR amplification of
TNF-RI was performed over 40 cycles (95°C for 20 sec-
onds, 60°C for 20 seconds, 72°C for 90 seconds). PCR
amplification of TNF-RII was performed over 40 cycles
(95°C for 20 seconds, 65°C for 20 seconds, 72°C for 90
seconds). The sequence of the resulting PCR products
was verified as TNF-RI and TNR-II. No-template con-
trols were negative.
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ELISA assays were performed in the linear range of ab-
sorbance using standard curves generated with recom-
binant proteins. The ELISA for CCL2 involved mouse
monoclonal antibodies (mAbs) against human CCL2
(#500-M71; PeproTech) for coating, and biotinylated
rabbit anti human CCL2 antibodies (#500-P34Bt; Pepro-
Tech) for detection. The ELISA for CXCL8 involved
mouse mAbs against human CXCL8 (#511502; BioLe-
gend) or rabbit polyclonal antibodies against human
CXCL8 (#500-P28; PeproTech) for coating, and biotinyl-
ated goat anti human CXCL8 antibodies (#BAF208;
R&D Systems) or biotinylated rabbit anti human CXCL8
antibodies (#500-P28Bt; PeproTech) for detection. The
ELISA for CCL5 involved mouse mAbs against human
CCL5 (#500-M75; PeproTech) for coating, and biotinyl-
ated goat anti human CCL5 antibodies (#BAF278; R&D
Systems) for detection. The ELISA for TNF-α involved
mouse mAbs against human TNF-α (#500-M26;
PeproTech) for coating, and biotinylated rabbit anti
human TNF-α antibodies (#500-P31ABt; PeproTech)
for detection. Following the addition of streptavidin–
horseradish peroxidase, the substrate TMB/E (Chemi-
con, Temecula, CA, USA) was added. The reaction was
stopped by addition of 0.18 M H2SO4, and was mea-
sured at 450 nm.
Immunohistochemistry
The expression of CCL2 by CAFs in biopsies of patients
diagnosed with invasive ductal carcinoma (IDC) was
determined as described previously [41]. Briefly, serial sec-
tions (5 μm thick) obtained from archived paraffin blocks
of patients were processed and stained by antibodies
against human CCL2. Staining was evaluated by a breast-
cancer specialized pathologist.
Western blotting
To determine the activation of activator protein 1 (AP-1)
and NF-κB, TNF-α stimulation was carried out at time
points that were determined by preliminary kinetics ana-
lyses (based on published literature and on our experience
in other cell systems; data not shown). In all of the experi-
ments described below, control cells were incubated with
the relevant vehicles of the reagents. The following pri-
mary antibodies were used: phosphorylated p65 (#3033;
Cell Signaling Technology, Danvers, MA, USA), total p65
(#4764; Cell Signaling Technology), phosphorylated c-Jun
(#1527-s; Epitomics, Burlingame, CA, USA), total c-Jun
(#610326; BD Transduction Laboratories, San Jose,
CA, USA) and IκBα (#4814; Cell Signaling Technol-
ogy). To determine the characteristics of patient CAFs
and of Tumor CM-derived CAFs, the following pri-
mary antibodies were used: pan-cytokeratin (#MA5-
13203; Thermo Fisher Scientific, Waltham, MA, USA),αSMA (#A-2547; Sigma-Aldrich and #ab5694; Abcam,
Cambridge, UK), vimentin (#sc-6260; Santa Cruz Biotech-
nology), FSP1 (#ab12480; Abcam) and FAPα (#sc-135069;
Santa Cruz Biotechnology). Loading controls were deter-
mined using antibodies against glyceraldehyde 3-
phosphate dehydrogenase (GAPDH; #ab9485; Abcam), β-
tubulin (#ab6046; Abcam) and Erk (#sc-154; Santa Cruz
Biotechnology), as indicated in the figures. After washing,
the membranes were incubated with the appropriate sec-
ondary antibodies. In all cases, conventional western blot
procedures were taken and membranes were subjected to
enhanced chemiluminescent (ECL) solution and X-ray
film.Migration of monocytic cells
Monocytic THP-1 cells were grown in suspension in
enriched RPMI medium and their migration in response
to CM of MSCs, stimulated or not stimulated by TNF-α,
was determined. To this end, MSCs were stimulated by
TNF-α (50 ng/ml) for 24 hours, while control cells were
exposed to the vehicle of the cytokine (0.1% BSA) in
DMEM starvation medium. Supernatants from control
and from stimulated cells were then collected and divided
into groups as follows: supernatants from untreated con-
trol MSCs; supernatants from TNF-α-stimulated MSCs,
treated by neutralizing antibodies against CCL2 (2 μg/ml,
#MAB679; R&D Systems); and supernatants from TNF-α-
stimulated MSCs, treated by isotype-matched nonrelevant
antibody (2 μg/ml, #401201; BioLegend). Recombinant
human CCL2 (rhCCL2) was used at 100 ng/ml as positive
control in the migration assays. rhCCL2 was either un-
treated or treated by neutralizing antibodies against CCL2
(as above). All antibody treatments were performed for 30
minutes at 37°C. The migration of human THP-1 mono-
cytic cells in response to these cell supernatants was
assessed by a 48-well modified Boyden chamber through a
polycarbonate polyvinylidene difluoride (PVDF) filter (8
μm pore size; Osmonics, Livermore, CA, USA). After 2
hours, the filters were fixed by methanol, and stained with
a Diff-Quik kit (Dade Behring, Dudingen, Switzerland).
The cells were counted in five high-power fields (HPF) by
light microscopy in triplicate.Statistical analyses
Student’s t test was used to calculate P values for ELISAs
and chemotaxis assays. P <0.05 was considered signifi-
cant. Adjustment for multiplicity of comparisons was
done using the Benjamini–Hochberg procedure. Using
this procedure, all of the significant results that were
presented in the manuscript remained statistically sig-
nificant after correcting for their multiplicity. The ELISA
results presented in the paper show a representative ex-
periment out of n ≥ 3 independent experiments that
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Figure 1A3,B2,B3, where the effect of Tumor CM on che-
mokine release was not consistent; therefore, in these
cases, the results are presented as mean ± standard devi-
ation of the different experiments (MSCs were given the
value of 1). The confocal pictures are representatives of
many pictures that were taken in at least three inde-
pendent experiments.
Results and discussion
The effects of long-term stimulation of MSCs by Tumor
CM on the inflammatory nature of the resulting CAFs
Published reports indicate that prolonged stimulation of
BM-derived human MSCs with breast tumor-derived
factors (Tumor CM) has led to conversion of MSCs intoFigure 1 Impact of prolonged stimulation by Tumor CM on the release of infla
were cultured with Tumor CM from MDA-MB-231 cells (MDA) (A) or MCF-7 cell
+ MCF-7 CM, respectively). Twenty-four hours after medium exchange to fresh
(A1, B1), CXCL8 (A2, B2) and CCL5 (A3, B3) was determined in comparison with
with the original Tumor CM of MDA-MB-231 or MCF-7 cells alone (MDA CM or
in the linear range of absorbance. (A1), (A2), (B1) Representatives of n = 3 indep
between MSCs and MSCs + Tumor CM were not consistent in different experim
mean ± standard deviation of normalized values (MSCs were given the value ofunctional CAFs that promoted tumor growth [11-14].
We began this study by determining the influence
of such tumor-derived factors on the inflammatory
traits of CAFs generated by MSCs exposed to Tumor
CM, using the expression of the inflammatory/
pro-malignancy chemokines CCL2, CXCL8 and CCL5
as readouts. To this end, we followed our published
procedure on generation of CAFs that are functional
in vivo in promoting breast cancer [13], by stimulat-
ing MSCs with Tumor CM for ~30 days. Following
such stimulation with Tumor CM of MDA-MB-231 and
MCF-7 breast tumor cells, the resulting cells have under-
gone conversion to CAF-like cells (to be termed herein
CAFs), as expected (Figure S2 in Additional file 1)
[12,13,82,83].mmatory chemokines by the resulting CAFs. Human BM-derived MSCs
s (B) over a prolonged period of time (~30 days; MSCs + MDA CM or MSCs
Tumor CM, cell supernatants were collected and the expression of CCL2
supernatants of MSCs that were not supplemented with CM (MSCs) and
MCF-7 CM, respectively). Chemokine expression was determined by ELISA,
endent experiments that have shown similar results. (A3), (B2), (B3) Ratios
ental repeats. Therefore, in these panels, the findings are presented as
f 1) obtained in relevant experimental repeats (at least n = 3).
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only partly accompanied by enhanced inflammatory pro-
file of the resulting CAFs. Tumor CM of MDA-MB-231
cells has increased the release of CCL2 and CXCL8 but
not of CCL5 (Figure 1A), while Tumor CM of MCF-7 cells
did not promote the release of CXCL8 and CCL5 by the
Tumor CM-generated CAFs (Figure 1B2,B3) and downreg-
ulated the expression of CCL2 by the cells (Figure 1B1).
These results indicate that when CAFs are generated by
exposure to breast tumor-derived factors, the process
leads to only marginal increases in the inflammatory
phenotype of the resulting CAFs. Moreover, only the CM
of the more aggressive MDA-MB-231 breast tumor cells
upregulated chemokine production by the resulting CAFs,
revealing heterogeneity in the content of the factors pro-
duced by different breast tumor cells and in their impact
on the expression of inflammatory traits by CAFs. The
content of Tumor CM is complex (for example [6,62,84]);
thus, the identity of the factors regulating the expression
of the different chemokines is yet to be explored and the
question of whether these same factors also induce the
conversion of MSCs to CAFs needs to be addressed in fu-
ture studies.
TNF-α prominently induces the release of pro-cancerous
chemokines by Tumor CM-generated CAFs and by patient
CAFs
TNF-α and IL-1β are highly expressed by cancer cells of
patients in human breast tumors (and also by adjacent
stromal cells and leukocytes). Of the two cytokines,
TNF-α is of particular interest because of its divergent
and at times opposing roles in the TME, and also because
it induces the release of inflammatory chemokines by
breast tumor cells and normal tissue cells (for example
[41,85-87]). Also, as we show in Figure S3 in Additional
file 1, the expression of TNF-RI and TNF-RII was denoted
in MSCs. Thus, we questioned what is the impact of
TNF-α on the inflammatory traits of CAFs derived from
MSCs stimulated by Tumor CM. Breast tumor cells are
known to lose in culture the capacity to release endogen-
ous inflammatory cytokines, such as TNF-α or IL-1β (lack
of endogenous TNF-α expression is shown in Figure S4 in
Additional file 1, under nontransfected and control vector
cells; results for IL-1β are not shown). Therefore, we
have used exogenous TNF-α for stimulating the CAFs that
were generated from MSCs by Tumor CM. We then deter-
mined the release of the inflammatory chemokines by the
stimulated cells (Figure 2).
To determine the effects of TNF-α stimulation on
Tumor CM-generated CAFs, MSCs that were exposed to
Tumor CM for ~30 days were stimulated by TNF-α dur-
ing the last 24 hours of culture (MSCs + MDA CM +
TNF-α or MSCs + MCF-7 CM + TNF-α) followed by de-
termination of CCL2, CXCL8 and CCL5 expression incell supernatants. In parallel, chemokine expression was
determined in MSCs that were exposed to Tumor CM
alone for the same prolonged time period (MSCs +
MDA CM or MSCs + MCF-7 CM) and in MSCs that
were grown in culture for ~30 days without Tumor CM
and were then stimulated by TNF-α during the last 24
hours (MSCs + TNF-α). The results shown in Figure 2
demonstrate that when CAFs were generated by pro-
longed exposure of MSCs to Tumor CM, the resulting
CAFs responded to TNF-α by elevated release of CCL2,
CXCL8 and CCL5. In parallel, stimulation of MSCs by
TNF-α has also induced the release of the three chemo-
kines (Figure 2). However, there were no significant dif-
ferences in chemokine levels induced by stimulation of
Tumor CM-generated CAFs with TNF-α when compared
with stimulation of MSCs by TNF-α (two right-hand bars
in Figure 2). These results indicate that Tumor CM did
not cooperate with TNF-α in upregulating chemokine
release and did not have much of an added value. TNF-α
thus had a dominant role in inducing the inflammatory
traits in Tumor CM-generated CAFs and in MSCs.
Moreover, TNF-α induced the release of the inflamma-
tory chemokines even when the Tumor CM alone (as
shown in Figure 1 for CCL5 stimulation by MDA CM
and for CXCL8 and CCL5 stimulation by MCF-7 CM)
had no effect. These results indicate that the different
chemokines are commonly regulated by TNFα, unlike
their differential response to breast Tumor CM.
These findings suggest that, following their recruit-
ment to the tumor site, MSCs are exposed to tumor
constituents that promote their differentiation to CAFs
and to some extent can also elevate their ability to re-
lease pro-malignancy chemokines. However, since the
TME is enriched with TNF-α released by the tumor cells,
this inflammatory cytokine turns into a most powerful
inducer of chemokine release by CAFs. TNF-α thus en-
riches the TME with high levels of inflammatory/
tumor-promoting chemokines presenting many dele-
terious pro-cancerous effects.
To examine the potential clinical relevance of these
observations we tested the content of inflammatory che-
mokines in CAFs obtained directly from a lung metasta-
sis of a breast cancer patient (CAFs #1) and from a
different patient’s primary breast tumor (CAFs #2). Two
such CAF isolates showed production of CCL2 and of
CXCL8 (Figure 3A1 and 3B1, respectively). Both patient
CAF isolates did not secrete CCL5 (Figure 3A1,B1).
To better understand the regulation of chemokine re-
lease by patient CAFs, we asked whether CCL5 – which
was not released constitutively by these cells – would be
upregulated by inflammatory cytokines such as TNF-α
and IL-1β that are known to prevail at the TME of
breast tumors. Indeed, in line with the expression of
both TNF-RI and TNF-RII by the two patient CAF
Figure 2 TNF-α induces potent elevation in inflammatory traits in MSCs and Tumor-CM-generated CAFs. Human BM-derived MSCs were
cultured with Tumor CM from MDA-MB-231 cells (MDA) (A) or from MCF-7 cells (B) over a prolonged period of time (~30 days). TNF-α
(50 ng/ml) or its vehicle (in control cells) was added for the last 24 hours. Expression of CCL2, CXCL8 and CCL5 was then determined in
supernatants of the cells. (A) Expression of the chemokines in the four experimental groups included in the study: MSCs grown in culture
for ~30 days without any additional stimulus (MSCs); MSCs grown in culture for ~30 days in the presence of Tumor CM derived from
MDA-MB-231 cells (MSCs + MDA CM); MSCs grown in culture for ~30 days and stimulated by TNF-α at the last 24 hours of culture (MSCs +
TNF-α); and MSCs grown in culture for ~30 days in the presence of Tumor CM derived from MDA-MB-231 cells and stimulated by TNF-α at
the last 24 hours of culture (MSCs + MDA CM + TNF-α). Expression of CCL2 (A1), CXCL8 (A2) and CCL5 (A3) was determined by ELISA, in the
linear range of absorbance. (B) Experimental design as in (A), but with MCF-7-derived CM. In each panel, the findings are representatives of
at least n = 3 experiments that have shown similar results. In comparisons between MSCs and all other groups: *P <0.05, **P ≤0.01, ***P
≤0.001. NS, not significant. #Differences between the two indicated groups have shown variability in n ≥ 3 independent experiments and
overall were not significant.
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responded to TNF-α with increased release of CCL5
(Figure 3A2,B2). Similar upregulation of CCL5 expression
was observed after stimulation by IL-1β (Figure 3A2,B2),
suggesting that chemokine induction by inflammatory cy-
tokines may be a general effect and not necessarily limited
to TNF-α. These findings support the clinical relevance of
our previous findings, showing that TNF-α upregulated
CCL5 in CAFs generated from MSCs by MDATumor CM
(Figure 2A3) and by MCF-7 Tumor CM (Figure 2B3), andsuggest that they reflect the clinical conditions of breast
cancer.
Overall, the results obtained in this part of the study
indicate that while tumor constituents had marginal ef-
fects on the inflammatory traits of Tumor CM-generated
CAFs, the effects of the inflammatory microenvironment
– represented here by TNF-α – were more prominent
and may lead to pronounced upregulation of inflamma-
tory chemokines in the TME. TNF-α and IL-1β highly
prevail in breast tumors, and thus the inflammatory
Figure 3 Basal and cytokine-induced release of inflammatory chemokines by patient CAFs. CAFs were isolated from lung metastasis of a breast
cancer patient (CAFs #1) or from a primary tumor of a different breast cancer patient (CAFs #2). (A1, B1) Expression of the pro-malignancy
chemokines CCL2, CXCL8 and CCL5 was determined by ELISA, in the linear range of absorbance. (A2, B2) Expression of CCL5 was determined
following TNFa and IL-1β stimulation (TNF-α, 50 ng/ml; IL-1β, 500 pg/ml; 48 hours). Control cells were stimulated by vehicle. Expression of the
chemokines was determined by ELISA, in the linear range of absorbance. In all panels, the findings are representatives of at least n = 3
independent experiments that have shown similar results.
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inflammatory cytokines may form the basis of inflam-
mation–stroma associations that promote breast cancer
progression in patient tumors.
TNF-α amplifies the inflammatory phenotype of MSCs by
activating TNF-RI and TNF-RII
MSCs that populate tumors are candidates for activation
by inflammatory factors that are present at the TME.
The findings shown in Figure 4A indicate that, following
stimulation by TNF-α, CXCL8 was the chemokine most
prominently induced in MSCs, followed by CCL2 and
then CCL5, which underwent relatively low levels of in-
duction. Moreover, the elevations in CCL2, CXCL8 and
CCL5 production obtained in TNF-α-stimulated MSCs
were recapitulated by CM of MDA-MB-231 breast tumor
cells that were transfected to express TNF-α (Figure S5 in
Additional file 1). Specifically, TNF-α expression by the
tumor cells led to prominent upregulation of CCL2,
CXCL8 and CCL5 production by MSCs (Figure S5 in
Additional file 1). The inflammatory impact was not
limited to TNF-α but was also detected following stimula-
tion of MSCs by exogenous IL-1β (Figure S6 in Additional
file 1). Overall, all three chemokines – CCL2, CXCL8 andCCL5 – were induced in MSCs by the inflammatory cyto-
kines TNF-α and IL-1β, suggesting that they all may be
upregulated in the TME by inflammatory mediators that
are highly prevalent at breast tumor sites.
Of the three chemokines induced in MSCs by TNF-α,
CCL2 was of most interest to us. This chemokine is
highly versatile and promotes the inflammatory and pro-
cancerous nature of the TME by acting at many diver-
gent levels, not all shared by CXCL8 and CCL5. Further-
more, CCL2 has very high relevance to our current study
because we discovered that it was expressed by CAFs
residing in proximity to human cancer cells in biopsies
of invasive ductal carcinoma (IDC) patients (Figure 5).
To further understand the molecular mechanisms medi-
ating inflammation–stroma interactions, we focused on
the mechanisms mediating the process of TNF-α-induced
CCL2 secretion by MSCs. Using neutralizing antibodies
to TNF-RI and to TNF-RII, the secretion of CCL2 was
significantly inhibited compared with isotype-treated
controls (Figure 4B; inhibition of TNF-RI gave rise to 36
to 55% reduction in CCL2 secretion and inhibition of
TNF-RII to 34 to 54% reduction), indicating that both
receptors mediate the effects of TNF-α on CCL2 release
by MSCs (based on analyses combining the two antibodies
Figure 4 TNF-α upregulates the inflammatory profile of MSCs via receptors TNF-RI and TNF-RII. (A) Relative induction of CCL2, CXCL8 and CCL5
in MSCs by TNF-α. Human BM-derived MSCs were stimulated by TNF-α (50 ng/ml) for 24 hours and the expression of the inflammatory chemokines
CCL2, CXCL8 and CCL5 in supernatants of MSCs was determined by ELISA, in the linear range of absorbance. Results are from an experiment in
which all three chemokines were analyzed in parallel, and the ratios between the three chemokines are representatives of the values obtained
in many experimental repeats. (B) Human BM-derived MSCs were exposed to neutralizing antibodies against tumor necrosis factor receptors
TNF-RI and TNF-RII or nonrelevant isotype-matched control antibodies (Control Ab) 1 hour prior to stimulation with TNF-α (50 ng/ml), and in
the course of 24 hours of stimulation by the cytokine. Control, cells stimulated with vehicle. Expression of CCL2 was determined by ELISA, in the
linear range of absorbance. The findings are representatives of at least n = 3 independent experiments that have shown similar results.
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that the inhibition levels could not reach higher levels due
to insufficient neutralizing activities of the antibodies).
These findings are of major interest because TNF-RI is
abundant in most cell types, while the expression of TNF-
RII is not as promiscuous but nevertheless was found to
be upregulated in breast cancer [44,88-91].
Induction of inflammatory traits in MSCs by TNF-α is
tightly regulated by the NF-κB pathway
The AP-1 and NF-κB transcription factors are known to
induce the expression of inflammatory chemokines in
the immune context; however, their extent of involve-
ment in inducing such chemokines depends on the cell
type and stimulus. From the therapeutic perspective it iscrucial to know whether both or only one of these tran-
scription factors are mediating the response of MSCs to
inflammatory stimuli that give rise to increased produc-
tion of pro-malignancy chemokines. We began this part
of the study by determining the involvement of AP-1 in
induction of CCL2 and CXCL8, the two inflammatory
chemokines that we found to be most relevant to the
clinical setting, as shown by their expression by patient
CAF isolates #1 and #2 (Figure 3). While AP-1 was acti-
vated by TNF-α stimulation of MSCs, it did not play a
role in inducing CCL2 and CXCL8 (Figure 6). Specific-
ally, in response to TNF-α, c-Jun – the active component
of AP-1 – was rapidly induced in MSCs (possibly due to
elevated stability), as was the phosphorylated form of c-
Jun (Figure 6A). However, downregulation of c-Jun
Figure 5 CCL2 is expressed by CAFs localized in vicinity to breast cancer cells in tumors of invasive ductal carcinoma (IDC) patients. CCL2
expression was determined by immunohistochemistry in biopsy sections of patients diagnosed with IDC: (A) IDC #1, (B) IDC #2. CCL2 staining
was detected in cancer cells and in adjacent fibroblasts. Some of the CCL2-expressing CAFs are indicated by arrows.
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tion in CCL2 and CXCL8 expression following TNF-α
stimulation (Figure 6B2; impact on CCL2 was in the
range of 21% inhibition to 33% increase and for CXCL8
was in the range of 29% inhibition to 27% increase).
Different results were obtained for NF-κB, showing
that this transcription factor is cardinal in CCL2 and
CXCL8 upregulation by TNF-α in MSCs. First, we found
that TNF-α stimulation induced significant reduction in
the expression levels of IκBα, the negative regulator of
the NF-κB pathway, in MSCs (Figure 7A). Similar results
were obtained in TNF-α-stimulated Tumor CM-derived
CAFs, as well as in patient CAFs (Figure 7B,C). In paral-
lel, p65 was activated by TNF-α stimulation of MSCs
(Figure 7D) and direct roles for NF-κB in CCL2 and
CXCL8 induction were revealed when p65 was downreg-
ulated by siRNA to p65 (Figure 7E1). Specifically, p65
knockdown by siRNA resulted in almost complete inhib-
ition of CCL2 (78 to 88%) and CXCL8 (82 to 90%) re-
lease by TNF-α-stimulated MSCs (Figure 7E2).
In contrast to the results obtained with TNF-α stimula-
tion, a different pattern was obtained with regards to the
impact of Tumor CM on the cells: while factors releasedby tumor cells resulted in MSC conversion to CAFs
(Figure S2 in Additional file 1) and to elevated release of
some of the inflammatory chemokines (Figure 1), no ac-
tivation of the NF-κB pathway was observed in MSCs
exposed to Tumor CM (Figure 7B). Here, we need to
take into account the fact that the cells were exposed to
Tumor CM for 1 month and thus it is possible that the
rapid NF-κB activation signals could no longer be
detected.
To summarize, the results of this part of the study
clearly indicate an NF-κB-based pathway that regulates
the expression of inflammatory and pro-malignancy che-
mokines such as CCL2 and CXCL8 in MSCs and in
CAFs in response to TNF-α. NF-κB, but not AP-1, was
involved in TNF-α-induced inflammatory patterns of
CAFs and MSCs, despite the fact that the promoter do-
mains of both these chemokines contain binding sites
for c-Jun. This dichotomy between the NF-κB and AP-1
transcription factors in controlling CCL2 and CXCL8 pro-
duction in MSCs indicates that the inflammatory profile
of MSCs is tightly regulated. The preference of one tran-
scription factor over another needs to be considered when
potential therapeutic measures are directed to intracellular
Figure 6 Induction of CCL2 and CLXL8 in TNFα-stimulated MSCs is not mediated via the AP-1 pathway. (A) Human BM-derived MSCs were stimu-
lated by TNF-α (50 ng/ml) for 5 and 10 minutes. Control cells were treated by the vehicle of TNF-α. c-Jun levels and phosphorylation were deter-
mined by western blot (WB) analyses. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as loading control. (B) Human BM-derived
MSCs were transiently transfected by small interfering RNA (siRNA) to c-Jun or by control siRNA. (B1) c-Jun expression was determined by WB ana-
lyses. β-Tubulin was used as loading control. (B2) Following siRNA transfection, the cells were stimulated by TNF-α (25 ng/ml; in this part of the
study we used a suboptimal concentration of TNF-α in order to facilitate detection of inhibitory effects) for 24 hours. Expression levels of CCL2
and CXCL8 in the supernatants of the cells were determined by ELISA, in the linear range of absorbance. #siRNA to c-Jun has yielded minor in-
creases or reductions in CCL2 and CXCL8 secretion in different experiments (see Results and discussion), and thus overall there was no significant
effect on CCL2 and CXCL8 secretion. In all panels, the findings are representatives of n = 3 independent experiments that have shown
similar results.
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progression, such as NF-κB and AP-1.The inflammatory traits gained by MSCs following
stimulation by TNF-α lead to potential pro-cancerous
effects
Thus far, we have demonstrated that the inflammatory
cytokines TNF-α and IL-1β induced inflammatory traits
in CAFs and MSCs; furthermore, we have delineated the
molecular mechanisms involved in these processes. Tofollow on these observations, we asked whether the in-
flammatory traits induced by TNF-α in MSCs have func-
tional relevance to tumor-promoting events taking place
at the TME.
CCL2 induces the recruitment to tumors of myeloid
subpopulations that exert prominent pro-cancerous ef-
fects, including TAMs and MDSCs [17,67,71-75]. We
examined the in vitro migration of monocytic cells and
found that it was induced by supernatants of TNF-α-
stimulated MSCs (Figure 8), which have been previously
found to be enriched with CCL2 (Figures 2 and 4A).
Figure 7 NF-κB is essential in mediating TNF-α-induced release of chemokines by MSCs. (A) Human BM-derived MSCs were stimulated by
TNF-α (50 ng/ml) for 15 minutes. The levels of IκBα (the negative regulator of the NF-κB pathway) were determined by WB analyses. GAPDH
was used as a loading control throughout. (B) CAFs were generated by culturing MSCs with Tumor CM from MDA-MB-231 (MDA) or MCF-7
breast tumor cells over a prolonged period of time (~30 days). TNF-α (50 ng/ml) was added for the last 24 hours to MSCs + Tumor CM cells
and IκBα levels were determined by WB analyses. (C) CAF #1 cells were stimulated for 48 hours by TNF-α (50 ng/ml). IκBα levels were
determined by WB analyses. (D) Human BM-derived MSCs were stimulated with TNF-α (50 ng/ml) for 10 minutes. p65 phosphorylation was
determined by WB analyses. (E) Human BM-derived MSCs were transiently transfected by siRNA to p65 or by control siRNA. (E1) p65
expression was determined by WB analyses. (E2) Following siRNA transfection, the cells were stimulated by TNF-α (25 ng/ml; a suboptimal
concentration of TNF-α in order to facilitate detection of inhibitory effects) for 48 hours. Expression of CCL2 and CXCL8 in the supernatants of
the cells was determined by ELISA, in the linear range of absorbance. In all panels, the findings are representatives of n = 3 independent
experiments that have shown similar results.
Katanov et al. Stem Cell Research & Therapy  (2015) 6:87 Page 13 of 17Furthermore, this migratory response was absolutely
dependent on CCL2 because neutralization of this
chemokine abolished the increase in monocytic cell
migration in response to supernatants derived from
TNF-α-stimulated MSCs (Figure 8). These results sug-
gest that TNF-α, which is prevalent in the TME, acts
on MSCs that reside in the tumors, leading to high pro-
duction of CCL2 by these cells. This chemokine, in
turn, may induce the recruitment of deleterious mye-
loid infiltrates to the tumor and thus further promote
the malignant phenotype of the tumor. Chemokinepro-cancerous activities may thus not only be initiated
by the tumor cells directly, but may also be induced by
inflammatory factors of the TME acting on stromal
cells residing in proximity to the cancer cells.
Furthermore, our findings suggesting that MSC-derived
CCL2 promotes the recruitment of TAMs and MDSCs
to breast tumors emphasize the important roles of inflam-
mation–stroma interactions. These findings gain high
relevance with the fact that CCL2 is indeed expressed
in breast cancer cells, as we have shown in our study of
biopsies of invasive ductal carcinoma patients (Figure 5).
Figure 8 MSCs promote monocyte migration through TNF-α-induced secretion of CCL2. Supernatants (sups) were collected from human BM-de-
rived MSCs that were stimulated by TNF-α (50 ng/ml) or by its vehicle for 24 hours. Thereafter, the sups were incubated with neutralizing antibodies for
CCL2 or with nonrelevant isotype-matched control antibody (I.C.) for 30 minutes. The migration of monocytic cells in response to control medium (with-
out chemokine), to recombinant human CCL2 (rhCCL2; 100 ng/ml) or to sups from TNF-α-stimulated or TNF-α nonstimulated MSCs was determined
by Boyden chamber migration assays. Cells were counted under a high-power field (HPF). The findings are representatives of n = 3 independent exper-
iments that have shown similar results.
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Much prominence has been given to inflammation-
driven activities that promote tumor progression by act-
ing on cancer cells, infiltrating leukocytes and adjacent
stromal cells. In the current study we provide new find-
ings on the networks that control the inflammatory
phenotype of CAFs and MSCs, demonstrating key roles
for the inflammatory cytokines TNF-α and IL-1β in up-
regulating the release of inflammatory, tumor-promoting
chemokines by these two cell types.
TNF-α and IL-1β are highly relevant to the inflamma-
tory setup of breast tumors [41-49]. They are minimally
expressed by normal breast epithelial cells while their
expression by breast tumor cells was detected in ~85%
of breast tumors in patients; elevated incidence of TNF-α
and IL-1β expression was highly correlated with relapsed
and advanced disease [41-49]. In the current study we
found that TNF-α upregulated the inflammatory pheno-
type of Tumor CM-derived CAFs and patient-derived
CAFs, manifested by the increased release of CCL2,
CXCL8 and CCL5 which are inflammatory chemokines
having strong tumor-promoting activities in general and
in breast cancer, particularly when derived from stroma
cells [4,21,54-70]. TNF-α was also demonstrated to be a
key inducer of inflammatory characteristics in MSCs,
with activities that were much more pronounced and
general than those induced by tumor constituents
(Tumor CM). As a result of TNF-α stimulation, the stro-
mal cells acquired the ability to release high levels of
CCL2, CXCL8 and CCL5. The increased release of these
chemokines from CAFs and MSCs may lead to exacer-
bated inflammatory and pro-cancerous nature of the
TME and, based on our results (Figure 8), may lead toincreased levels of deleterious myeloid infiltrates in
breast tumors. The findings of our study thus suggest
that stromal cells located near the cancer cells have a
major role in promoting the inflammatory nature of the
TME. Overall, a coordinated inflammatory network may
be established at the tumor site between the cancer cells
and stromal cells, set up by inflammatory cytokines such
as TNF-α and IL-1β.
In this study we have also revealed the important role
of NF-κB, but not of AP-1, in mediating the activities of
TNF-α on MSCs and CAFs. These findings support other
reports [10,92,93], indicating that the NF-κB pathway is
a key cellular component that controls inflammatory
events at the TME. The ultimate need for NF-κB activa-
tion in this process provides novel insights into specifi-
city in regulatory pathways and may thus have clinical
therapeutic implications. This need shows that NF-κB
may be a preferred target for inhibition and that its roles
are not limited to the tumor cells themselves and to in-
filtrating leukocytes [94,95], but rather extend to stromal
cells at the tumor milieu. Thus, our study strongly sup-
ports the positioning of NF-κB as a master regulator that
may serve as a therapeutic target, whose inhibition may
lead to significant downregulation of inflammatory, pro-
cancerous events in the entire tumor.
Currently, the inhibition of NF-κB in cancer has not
entered the stage of clinical trials, and may be hampered
by the fact that this pathway regulates a number of es-
sential cellular processes and immune activities. Such
hurdles can be overcome by directing the NF-κB-
inhibiting modalities to specific target cells, in which this
transcription factor is the key inducer of undesired in-
flammatory, tumor-promoting effects. In this respect,
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could serve as appropriate targets for NF-κB inhibition,
through which downregulation of the inflammatory TME
could be achieved.
Additional file
Additional file 1: Presents the following additional data. Figure S1.
verifying the purity and mesenchymal phenotype of patient-derived CAF
isolates. Figure S2. showing that human BM-derived MSCs, exposed for
~30 days to Tumor CM, undergo transition to CAFs. Figure S3. showing
that TNF-RI and TNF-RII are expressed by human BM-derived MSCs and
by patient-derived CAFs. Figure S4. showing that breast tumor cells
transfected with TNF-α-expressing vector release high TNF-α levels. Figure
S5. showing that TNF-α produced by breast tumor cells induces chemokine
release by MSCs. Figure S6. showing that stimulation by IL-1β upregulates
the release of the inflammatory chemokines CCL2, CXCL8 and CCL5 by MSCs.
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